Peripheral blood cell counts as biomarkers of clinical benefit in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) receiving immune checkpoint inhibitor (ICI) combination (combo) therapies.

Ardit Feinaj; Kaizen Nathani; Amina Touma; Roy Elias; Maximilian Pallauf; Mark Christopher Markowski; Michael Anthony Carducci; Nirmish Singla; Yasser Ged

doi:10.1200/JCO.2024.42.4_suppl.446

Peripheral blood cell counts as biomarkers of clinical benefit in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) receiving immune checkpoint inhibitor (ICI) combination (combo) therapies.

Ardit Feinaj (First author), Kaizen Nathani, Amina Touma, Roy Elias, Maximilian Pallauf, Mark Christopher Markowski, Michael Anthony Carducci, Nirmish Singla, Yasser Ged

The James Buchanan Brady Urological Institue - Department of Urology - Johns Hopkins School of Medicine

Research output: Contribution to journal › Abstract (Journal) › peer-review

Original language	American English
Pages (from-to)	446-446
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	42
Issue number	4_SUPPL
DOIs	https://doi.org/10.1200/JCO.2024.42.4_suppl.446
Publication status	Published - 1 Feb 2024
Externally published	Yes
Event	ASCO Genitourinary Cancer Symposium - San Francisco, United States Duration: 25 Jan 2024 → 27 Jan 2024

Access to Document

10.1200/JCO.2024.42.4_suppl.446

Cite this

Feinaj, A., Nathani, K., Touma, A., Elias, R., Pallauf, M., Markowski, M. C., Carducci, M. A., Singla, N., & Ged, Y. (2024). Peripheral blood cell counts as biomarkers of clinical benefit in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) receiving immune checkpoint inhibitor (ICI) combination (combo) therapies. Journal of Clinical Oncology, 42(4_SUPPL), 446-446. https://doi.org/10.1200/JCO.2024.42.4_suppl.446

@article{ec52ba265055476abbbb19949e0ea80d,

title = "Peripheral blood cell counts as biomarkers of clinical benefit in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) receiving immune checkpoint inhibitor (ICI) combination (combo) therapies.",

author = "Ardit Feinaj and Kaizen Nathani and Amina Touma and Roy Elias and Maximilian Pallauf and Markowski, {Mark Christopher} and Carducci, {Michael Anthony} and Nirmish Singla and Yasser Ged",

year = "2024",

month = feb,

day = "1",

doi = "10.1200/JCO.2024.42.4_suppl.446",

language = "American English",

volume = "42",

pages = "446--446",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins ",

number = "4_SUPPL",

note = "ASCO Genitourinary Cancer Symposium ; Conference date: 25-01-2024 Through 27-01-2024",

}

Feinaj, A, Nathani, K, Touma, A, Elias, R, Pallauf, M, Markowski, MC, Carducci, MA, Singla, N & Ged, Y 2024, 'Peripheral blood cell counts as biomarkers of clinical benefit in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) receiving immune checkpoint inhibitor (ICI) combination (combo) therapies.', Journal of Clinical Oncology, vol. 42, no. 4_SUPPL, pp. 446-446. https://doi.org/10.1200/JCO.2024.42.4_suppl.446

Peripheral blood cell counts as biomarkers of clinical benefit in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) receiving immune checkpoint inhibitor (ICI) combination (combo) therapies. / Feinaj, Ardit (First author); Nathani, Kaizen; Touma, Amina et al.
In: Journal of Clinical Oncology, Vol. 42, No. 4_SUPPL, 01.02.2024, p. 446-446.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Peripheral blood cell counts as biomarkers of clinical benefit in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) receiving immune checkpoint inhibitor (ICI) combination (combo) therapies.

AU - Feinaj, Ardit

AU - Nathani, Kaizen

AU - Touma, Amina

AU - Elias, Roy

AU - Pallauf, Maximilian

AU - Markowski, Mark Christopher

AU - Carducci, Michael Anthony

AU - Singla, Nirmish

AU - Ged, Yasser

PY - 2024/2/1

Y1 - 2024/2/1

U2 - 10.1200/JCO.2024.42.4_suppl.446

DO - 10.1200/JCO.2024.42.4_suppl.446

M3 - Abstract (Journal)

SN - 0732-183X

VL - 42

SP - 446

EP - 446

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 4_SUPPL

T2 - ASCO Genitourinary Cancer Symposium

Y2 - 25 January 2024 through 27 January 2024

ER -

Feinaj A, Nathani K, Touma A, Elias R, Pallauf M, Markowski MC et al. Peripheral blood cell counts as biomarkers of clinical benefit in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) receiving immune checkpoint inhibitor (ICI) combination (combo) therapies. Journal of Clinical Oncology. 2024 Feb 1;42(4_SUPPL):446-446. doi: 10.1200/JCO.2024.42.4_suppl.446